Protein-based nanoparticle vaccine for metapneumovirus
AssigneeIcosavax, Inc.
InventorsAndrew Lawrence Feldhaus, Douglas Andrew Holtzman, Clancey Buchanan Wolf
Life of this patent
Estimating the term…
Abstract
Provided are virus-like particle vaccines for human metapneumovirus (hMPV) in which the ectodomain of hMPV F protein is linked to, and thereby displayed on, a symmetric protein-based virus-like particle. For example, the vaccine antigen may be a N-terminal fusion of the ectodomain of hMPV F protein to a protein having a multimerization domain for a one- or two-component virus-like particle, such as a two-component icosahedral virus-like particle. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to hMPV.
Claims30
A protein-based virus-like particle (VLP), comprising a first component and a second component;
- wherein the first component comprises a first protein, wherein the first protein is a fusion protein comprising a human metapneumovirus (hMPV) F protein ectodomain and a first multimerization domain sharing at least 90% identity to SEQ ID NO:
- 7;
- and
- wherein the second component comprises a second protein, the second protein comprising a second multimerization domain sharing at least 90% identity to SEQ ID NO:
- 8.
A polynucleotide encoding a protein-based virus-like particle (VLP), comprising a first component and a second component;
- wherein the first component comprises a first protein, wherein the first protein is a fusion protein comprising a human metapneumovirus (hMPV) F protein ectodomain and a first multimerization domain sharing at least 90% identity to SEQ ID NO:
- 7;
- and
- wherein the second component comprises a second protein, the second protein comprising a second multimerization domain sharing at least 90% identity to SEQ ID NO:
- 8.
A method of immunizing a subject against infection by human metapneumovirus, the method comprising administering a protein-based virus-like particle (VLP), comprising a first component and a second component;
- wherein the first component comprises a first protein, wherein the first protein is a fusion protein comprising a human metapneumovirus (hMPV) F protein ectodomain and a first multimerization domain sharing at least 90% identity to SEQ ID NO:
- 7;
- and
- wherein the second component comprises a second protein, the second protein comprising a second multimerization domain sharing at least 90% identity to SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.